Based on the hypothesis that the phenotype of CTCs may reflect the phenotype of metastatic disease, characterization of CTCs may be useful for reassessment of HER2 status and additional therapeutic markers [20]. The gene discussed is ERBB2; the disease is metastatic neoplasm.